Alerts

PIP breast implants are known to have been used in Australia from September 1999 until April 2010, when non-implanted PIP breast implants were recalled from the market following advice from the French regulator (AFSSAPS) that in making these devices the manufacturer had used unapproved materials which may affect their safety and performance.

Certain batches of Clexane (enoxaparin) have been recalled because of an impurity. Stop using it, check with your healthcare provider, and return any affected product. If you have concerns, consult your doctor.

Read information for consumers and health professionals about low levels of nitrosamine impurity in medicines containing duloxetine.

Recall for product correction due to fire risk from faulty component.

Poly Implant Prothèse (PIP) update

Poly Implant Prothèse (PIP) update

Poly Implant Prothèse (PIP) update

Clexane (enoxaparin) is being recalled due to contamination concerns, and patients should check with their doctor or pharmacist to see if their supply is affected.

Safety alert due to higher-than-expected revision rate when used without patella resurfacing.

Recall due to potential for incorrect blood glucose results.

TGA has issued updated safety advice for consumers taking Pradaxa (dabigatran), highlighting risks such as bleeding and the importance of proper storage and patient monitoring.

The TGA advises that while PIP breast implants were recalled due to the use of unauthorised silicone, current evidence does not support routine removal in patients without symptoms, and individuals are encouraged to seek medical advice if concerned.

Consumers should stop using Clexane (enoxaparin) from the newly recalled batch due to impurity concerns. Check with your doctor or pharmacist to see if your supply is affected and return any contaminated product. If you have any concerns, consult your doctor.

Continuing Australian reporting of bizarre and sometimes dangerous sleep related behaviours such as sleep walking and sleep driving in some users of zolpidem.

We are aware of an emerging trend for telehealth providers to offer compounded semaglutide-like products. Compounded semaglutide-like products are ‘unapproved’ therapeutic goods and have not been evaluated by us for safety, quality and efficacy.

Update to Mesh Hub notifying of recent recall actions

Only certain types of specialists will be able to prescribe hydroxychloroquine to new patients

Recall for product correction for Medtronic SynchroMed II and SynchroMed EL implantable infusion pumps.

Poly Implant Prothèse (PIP) update

Information on the management of issues related to the recall of PIP silicone gel breast implants

In October 2009 an anaphylactic reaction to the Panvax H1N1 pandemic influenza vaccine was reported in Western Australia in a person known to have a pre-existing latex allergy.

Read our safety advisory about this ingredient's potential to cause severe allergic reactions including anaphylaxis.

Poly Implant Prothèse (PIP) update

Poly Implant Prothèse (PIP) update